Cross-Sector entity
Of the tracked stories, 2 of 2 also mention Department of Pharmaceuticals, the most common co-covered peer. Coverage clusters in fda-approval, which accounts for 1 of those 2, with the remainder spread across 1 other category. Each carries 2 original sources on average.
2 verified stories tracked
Last mentioned: Aug 7, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Department of Pharmaceuticals, the most common co-covered peer. Coverage clusters in fda-approval, which accounts for 1 of those 2, with the remainder spread across 1 other category. Each carries 2 original sources on average. We currently track 2 Cross-Sector stories that mention Manoj Joshi, all published on August 7, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Manoj Joshi. Shared-story counts are live from our verified record — not editorial picks.
The 9th India Medical Device 2026 conference offers biotech and pharma companies a clear signal to diversify into the device sector, as the government pushes for domestic manufacturing and innovation. Regulatory sentiment is shifting to support local production, opening new market adjacencies.
At the 9th India Medical Device 2026 conference, policymakers underscored the shift from import reliance to domestic manufacturing to improve healthcare access and device quality. A white paper on service and maintenance was released, signaling a holistic approach to the device lifecycle.
Source: newkerala.com · aninews.in
